drugset / Trial / NCT00749723
Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
Non-randomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to improve overall survival while maintaining a good quality of life in pediatric patients with refractory or recurrent brain tumors (medulloblastomas, supratentorial PNETs, ependymomas WHO grade II and III). Response to different chemotherapy options (intravenous versus oral chemotherapy, intraventricular chemotherapy) as part of a multimodal therapy will be assessed. Progression-free, overall survival and toxicity will be evaluated additionally.
Timeline
- Start
- 2006-02-01
- Primary completion
- 2015-01-31
- Completion
- 2016-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 0.7 mg | Intravenous |
| Subject | Etoposide | Small molecule | 1 mg | Intravenous |
| Subject | Etoposide | Small molecule | 25 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |
| Subject | Thiotepa | Other / unclassified | — | — |
| Subject | Trofosfamide | Small molecule | 100 mg/m2 | Oral |